Other Events ·
Silexion Therapeutics Corp published an updated corporate presentation on August 10, 2026, detailing the clinical…
SLXNWSilexion Therapeutics Corp
Silexion Therapeutics Corp published an updated corporate presentation on August 10, 2026, detailing the clinical development timeline for its lead product candidate, SIL 204. The company announced that a Phase 2/3 clinical program investigating the dual-delivery strategy of SIL 204 for locally advanced pancreatic cancer was initiated in July 2026 following regulatory approvals in Israel and Germany. Early human data from this trial is expected in Q4 2026, with expansion phases planned for 2027 and confirmatory trials starting in 2030. Silexion Therapeutics Corp operates in the biotechnology industry, developing RNA silencing therapeutics for oncology.